Newsroom

LOTTE BIOLOGICS announced on December 12th that it held the “Future Innovation Technology Development Forum” for employees at the multipurpose hall of the IBS Tower in Songdo.

Since last year, the company has been regularly hosting this forum, which focuses on the latest biopharmaceutical development and manufacturing technologies, in order to strengthen technological differentiation and collaboration in the global market. It also serves as a platform for knowledge exchange between employees at the Korea and New York Syracuse Bio Campuses.

This forum, the fifth in the series, featured Jae-Wook Jung, Head of R&D at GC Biopharma, as the main speaker, and was also attended by Byung-Chul Lee, CEO of Kanaph Therapeutics.

In his presentation, Jung introduced the current landscape of the biopharmaceutical industry and the latest trends related to ADCs (antibody–drug conjugates), delivering a talk under the theme “Evolving from traditional approaches to innovative breakthroughs.”

The presentation also covered an overview of GC Biopharma’s pipeline and the current status of its newly expanded ADC development efforts. It highlighted the limitations of traditional cytotoxic chemotherapy, noting that such treatments attack not only rapidly dividing cancer cells but also normal cells, thereby causing side effects. He went on to explain the differentiated advantages of ADCs, which minimize damage to normal cells by combining an antibody with an anticancer agent to deliver the drug selectively to cancer cells.

Jung stated, “We are conducting various research initiatives with highly capable partners, and in particular, through our collaboration with Kanaph Therapeutics, which possesses core ADC linker technologies, we are working to secure assets with greater value.”

He added, “As we target the global market with diverse therapeutic technologies—not only through early clinical data but also through joint research projects—LOTTE BIOLOGICS, with its manufacturing facility in New York, will be able to play a significant role.”

LOTTE BIOLOGICS’ ADC manufacturing facility at the New York Syracuse Bio Campus provides a one-stop CDMO (contract development and manufacturing) service that meets client needs from clinical development through commercial production.

In addition, LOTTE BIOLOGICS’ SoluFlex Link technology is an innovative conjugation platform that enables precise drug delivery and accurate target engagement for ADCs, thereby enhancing both therapeutic efficacy and safety. Based on a specially designed hydrophilicity-enhanced linker, the technology can be applied to a wide range of payloads and maintains high yield even under demanding conditions. It has demonstrated superior outcomes compared with existing ADC therapeutics in terms of in-vivo efficacy, pharmacokinetics, stability, and manufacturability, and is gaining attention as a suitable platform for next-generation ADC development and commercial production.

Meanwhile, since April of last year, LOTTE BIOLOGICS has been inviting world-renowned experts—including Professor Nathan Tumey, Ph.D., of the Department of Pharmaceutical Sciences at SUNY; Dr. Oren Beske of U.S. biotech company ATUM; Dr. Mark Chiu of Tavotek Biotherapeutics; and Dr. Jonny Finlay of Ottimo Pharma—to share the latest scientific information related to technology development. Through these sessions, the company continues to strengthen its global network and support employees in acquiring up-to-date knowledge.

Kern Chang, Head of Technology Development at LOTTE BIOLOGICS, stated, “LOTTE BIOLOGICS is commercializing innovative technologies based on its geopolitical strengths and quality competitiveness. As a global ADC CDMO, we will continue to advance and hope to contribute new therapeutic options to patients and the medical field.” End.